E. Sari Et Al. , "The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels," CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4, pp.270-274, 2014
Sari, E. Et Al. 2014. The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels. CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4 , 270-274.
Sari, E., Yazici, A., Eser, B., Erol, M. K., Kilic, A., Ermis, S. S., ... Koytak, A.(2014). The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels. CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4, 270-274.
Sari, ESİN Et Al. "The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels," CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4, 270-274, 2014
Sari, ESİN S. Et Al. "The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels." CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4, pp.270-274, 2014
Sari, E. Et Al. (2014) . "The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels." CUTANEOUS AND OCULAR TOXICOLOGY , vol.33, no.4, pp.270-274.
@article{article, author={ESİN SÖĞÜTLÜ SARI Et Al. }, title={The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels}, journal={CUTANEOUS AND OCULAR TOXICOLOGY}, year=2014, pages={270-274} }